Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Inhibition of the interleukin-6 signaling pathway: a strategy to induce immune tolerance.

Zhang C, Zhang X, Chen XH.

Clin Rev Allergy Immunol. 2014 Oct;47(2):163-73. doi: 10.1007/s12016-014-8413-3. Review.

PMID:
24647663
2.

Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.

Fasching P, Stradner M, Graninger W, Dejaco C, Fessler J.

Molecules. 2017 Jan 14;22(1). pii: E134. doi: 10.3390/molecules22010134. Review.

3.

Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.

Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, Ohsugi Y, Nishikawa T, Ripley B, Kimura A, Kishimoto T, Naka T.

Arthritis Rheum. 2008 Dec;58(12):3710-9. doi: 10.1002/art.24126.

4.

Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells.

Dominitzki S, Fantini MC, Neufert C, Nikolaev A, Galle PR, Scheller J, Monteleone G, Rose-John S, Neurath MF, Becker C.

J Immunol. 2007 Aug 15;179(4):2041-5.

5.

Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity.

Kosmaczewska A.

Int J Mol Sci. 2014 Oct 15;15(10):18574-92. doi: 10.3390/ijms151018574. Review.

6.

Inhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancer.

Ataie-Kachoie P, Pourgholami MH, Morris DL.

Cytokine Growth Factor Rev. 2013 Apr;24(2):163-73. doi: 10.1016/j.cytogfr.2012.09.001. Epub 2012 Oct 26. Review.

PMID:
23107589
7.

Therapeutic targeting of the interleukin-6 receptor.

Tanaka T, Narazaki M, Kishimoto T.

Annu Rev Pharmacol Toxicol. 2012;52:199-219. doi: 10.1146/annurev-pharmtox-010611-134715. Epub 2011 Sep 9. Review.

PMID:
21910626
8.

Biological effects of IL-21 on different immune cells and its role in autoimmune diseases.

Gharibi T, Majidi J, Kazemi T, Dehghanzadeh R, Motallebnezhad M, Babaloo Z.

Immunobiology. 2016 Feb;221(2):357-67. doi: 10.1016/j.imbio.2015.09.021. Epub 2015 Oct 1. Review.

PMID:
26466984
9.

Boosting interleukin-10 production: therapeutic effects and mechanisms.

Zhou X, Schmidtke P, Zepp F, Meyer CU.

Curr Drug Targets Immune Endocr Metabol Disord. 2005 Dec;5(4):465-75. Review.

PMID:
16375698
10.

Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo.

Glauben R, Sonnenberg E, Wetzel M, Mascagni P, Siegmund B.

J Biol Chem. 2014 Feb 28;289(9):6142-51. doi: 10.1074/jbc.M113.517599. Epub 2014 Jan 13.

11.

IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer.

Neurath MF, Finotto S.

Cytokine Growth Factor Rev. 2011 Apr;22(2):83-9. doi: 10.1016/j.cytogfr.2011.02.003. Epub 2011 Mar 5. Review.

PMID:
21377916
12.

Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade.

Jordan SC, Choi J, Kim I, Wu G, Toyoda M, Shin B, Vo A.

Transplantation. 2017 Jan;101(1):32-44. doi: 10.1097/TP.0000000000001452. Review.

PMID:
27547870
13.

Significance of T helper 17 immunity in transplantation.

Abadja F, Sarraj B, Ansari MJ.

Curr Opin Organ Transplant. 2012 Feb;17(1):8-14. doi: 10.1097/MOT.0b013e32834ef4e4. Review.

14.

Activation of natural killer T cells by α-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis.

Yoshiga Y, Goto D, Segawa S, Horikoshi M, Hayashi T, Matsumoto I, Ito S, Taniguchi M, Sumida T.

Clin Exp Immunol. 2011 May;164(2):236-47. doi: 10.1111/j.1365-2249.2011.04369.x. Epub 2011 Mar 10.

15.

Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.

Haruta H, Ohguro N, Fujimoto M, Hohki S, Terabe F, Serada S, Nomura S, Nishida K, Kishimoto T, Naka T.

Invest Ophthalmol Vis Sci. 2011 May 17;52(6):3264-71. doi: 10.1167/iovs.10-6272.

PMID:
21330657
16.

Anticytokine therapy in autoimmune diseases.

Nishimoto N, Kishimoto T, Yoshizaki K.

Intern Med. 1999 Feb;38(2):178-82. Review.

17.

Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis.

Aricha R, Mizrachi K, Fuchs S, Souroujon MC.

J Autoimmun. 2011 Mar;36(2):135-41. doi: 10.1016/j.jaut.2010.12.001. Epub 2010 Dec 30.

PMID:
21193288
18.

Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody.

Mihara M, Ohsugi Y, Kishimoto T.

Biofactors. 2009 Jan-Feb;35(1):47-51. doi: 10.1002/biof.9. Review.

PMID:
19319845
19.

Coordinated gene expression of Th17- and Treg-associated molecules correlated with resolution of the monophasic experimental autoimmune uveitis.

Jia X, Hu M, Wang C, Wang C, Zhang F, Han Q, Zhao R, Huang Q, Xu H, Yuan H, Ren H.

Mol Vis. 2011;17:1493-507. Epub 2011 Jun 7.

20.

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Jones SA, Scheller J, Rose-John S.

J Clin Invest. 2011 Sep;121(9):3375-83. doi: 10.1172/JCI57158. Epub 2011 Sep 1. Review.

Supplemental Content

Support Center